FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1587891922> ?p ?o ?g. }

• W1587891922 endingPage "1722" @default.
• W1587891922 startingPage "1707" @default.
• W1587891922 abstract "// Antonella Cusimano 1 , Roberto Puleio 2 , Natale D’Alessandro 3 , Guido R. Loria 2 , James A. McCubrey 4 , Giuseppe Montalto 1, 5 , Melchiorre Cervello 1 1 Institute of Biomedicine and Molecular Immunology “Alberto Monroy”, National Research Council, Palermo, Italy 2 Istituto Zooprofilattico Sperimentale della Sicilia “A. Mirri”, Area Diagnostica Specialistica, Laboratorio di Istopatologia ed Immunoistochimica, Palermo, Italy 3 Dipartimento di Scienze per la Promozione della Salute e Materno Infantile “G. D’Alessandro”, Università di Palermo, Palermo, Italy 4 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 5 Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy Correspondence to: Melchiorre Cervello, e-mail: melchiorre.cervello@ibim.cnr.it Keywords: HCC, AKT, mTOR, SC66, anoikis Received: August 22, 2014      Accepted: November 11, 2014      Published: December 19, 2014 ABSTRACT Hepatocellular carcinoma (HCC) is characterized by limited response to current drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. This was associated with alterations in cytoskeleton organization, a reduction in expression levels of E-cadherin, β-catenin and phospho-FAK, together with up-regulation of Snail protein levels. All these alterations were coupled with anoikis cell death induction. In addition, SC66 induced the production of reactive oxygen species (ROS) and DNA damage. Pre-treatment with the ROS scavenger N-Acetyl-cysteine (NAC) prevented SC66-induced cell growth inhibition and anoikis. SC66 significantly potentiated the effects of both conventional chemotherapeutic and targeted agents, doxorubicin and everolimus, respectively. In vivo , SC66 inhibited tumor growth of Hep3B cells in xenograft models, with a similar mechanism observed in the in vitro model. Taken together, these data indicate that the AKT inhibitor SC66 had antitumor effects on HCC cells. This was mediated by ROS production, induction of anoikis-mediated cell death and inhibition of the AKT cell survival pathway. Our results provide a rational basis for the use of SC66 in HCC treatment." @default.
• W1587891922 created "2016-06-24" @default.
• W1587891922 creator A5015791870 @default.
• W1587891922 creator A5017532687 @default.
• W1587891922 creator A5030391285 @default.
• W1587891922 creator A5034393372 @default.
• W1587891922 creator A5061469984 @default.
• W1587891922 creator A5070243247 @default.
• W1587891922 creator A5082733849 @default.
• W1587891922 date "2014-12-19" @default.
• W1587891922 modified "2023-09-30" @default.
• W1587891922 title "Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells" @default.
• W1587891922 cites W1529336528 @default.
• W1587891922 cites W1967532587 @default.
• W1587891922 cites W1969196690 @default.
• W1587891922 cites W1971837077 @default.
• W1587891922 cites W1973871728 @default.
• W1587891922 cites W1977267072 @default.
• W1587891922 cites W1981406217 @default.
• W1587891922 cites W1981989535 @default.
• W1587891922 cites W1983218872 @default.
• W1587891922 cites W1986913991 @default.
• W1587891922 cites W1987473368 @default.
• W1587891922 cites W1988508668 @default.
• W1587891922 cites W1995480433 @default.
• W1587891922 cites W1999163644 @default.
• W1587891922 cites W2000307707 @default.
• W1587891922 cites W2000731858 @default.
• W1587891922 cites W2015772717 @default.
• W1587891922 cites W2050244237 @default.
• W1587891922 cites W2055729918 @default.
• W1587891922 cites W2058887247 @default.
• W1587891922 cites W2066659565 @default.
• W1587891922 cites W2068837653 @default.
• W1587891922 cites W2073067473 @default.
• W1587891922 cites W2081167500 @default.
• W1587891922 cites W2087367170 @default.
• W1587891922 cites W2090672434 @default.
• W1587891922 cites W2090894302 @default.
• W1587891922 cites W2100628426 @default.
• W1587891922 cites W2145139438 @default.
• W1587891922 cites W2149998712 @default.
• W1587891922 cites W2150075935 @default.
• W1587891922 cites W2156871508 @default.
• W1587891922 cites W2158965278 @default.
• W1587891922 cites W2159732007 @default.
• W1587891922 cites W2162242700 @default.
• W1587891922 cites W2163130954 @default.
• W1587891922 cites W218930726 @default.
• W1587891922 cites W4238567307 @default.
• W1587891922 cites W4251667769 @default.
• W1587891922 doi "https://doi.org/10.18632/oncotarget.2738" @default.
• W1587891922 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4359326" @default.
• W1587891922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25596737" @default.
• W1587891922 hasPublicationYear "2014" @default.
• W1587891922 type Work @default.
• W1587891922 sameAs 1587891922 @default.
• W1587891922 citedByCount "25" @default.
• W1587891922 countsByYear W15878919222016 @default.
• W1587891922 countsByYear W15878919222017 @default.
• W1587891922 countsByYear W15878919222018 @default.
• W1587891922 countsByYear W15878919222019 @default.
• W1587891922 countsByYear W15878919222020 @default.
• W1587891922 countsByYear W15878919222022 @default.
• W1587891922 countsByYear W15878919222023 @default.
• W1587891922 crossrefType "journal-article" @default.
• W1587891922 hasAuthorship W1587891922A5015791870 @default.
• W1587891922 hasAuthorship W1587891922A5017532687 @default.
• W1587891922 hasAuthorship W1587891922A5030391285 @default.
• W1587891922 hasAuthorship W1587891922A5034393372 @default.
• W1587891922 hasAuthorship W1587891922A5061469984 @default.
• W1587891922 hasAuthorship W1587891922A5070243247 @default.
• W1587891922 hasAuthorship W1587891922A5082733849 @default.
• W1587891922 hasBestOaLocation W15878919221 @default.
• W1587891922 hasConcept C190283241 @default.
• W1587891922 hasConcept C2778019345 @default.
• W1587891922 hasConcept C502942594 @default.
• W1587891922 hasConcept C55493867 @default.
• W1587891922 hasConcept C71924100 @default.
• W1587891922 hasConcept C75217442 @default.
• W1587891922 hasConcept C86554907 @default.
• W1587891922 hasConcept C86803240 @default.
• W1587891922 hasConceptScore W1587891922C190283241 @default.
• W1587891922 hasConceptScore W1587891922C2778019345 @default.
• W1587891922 hasConceptScore W1587891922C502942594 @default.
• W1587891922 hasConceptScore W1587891922C55493867 @default.
• W1587891922 hasConceptScore W1587891922C71924100 @default.
• W1587891922 hasConceptScore W1587891922C75217442 @default.
• W1587891922 hasConceptScore W1587891922C86554907 @default.
• W1587891922 hasConceptScore W1587891922C86803240 @default.
• W1587891922 hasIssue "3" @default.
• W1587891922 hasLocation W15878919221 @default.
• W1587891922 hasLocation W15878919222 @default.
• W1587891922 hasLocation W15878919223 @default.
• W1587891922 hasLocation W15878919224 @default.
• W1587891922 hasLocation W15878919225 @default.
• W1587891922 hasLocation W15878919226 @default.
• W1587891922 hasLocation W15878919227 @default.

• next